Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
This weekend’s oncology conference will feature at least 30 different ADC projects.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.